Published in J Biol Chem on May 07, 2013
A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell (2014) 1.44
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res (2015) 0.98
Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun (2014) 0.97
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget (2014) 0.93
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer (2014) 0.89
HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression. Cancers (Basel) (2014) 0.85
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells. Mol Cell Biol (2014) 0.85
Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia (2015) 0.85
Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma. Br J Cancer (2014) 0.83
Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment. Cytokine Growth Factor Rev (2015) 0.83
Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. Br J Cancer (2014) 0.81
Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget (2015) 0.80
MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol (2015) 0.80
Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. Onco Targets Ther (2015) 0.79
Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. Sci Rep (2015) 0.78
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia (2015) 0.76
Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol (2017) 0.75
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J Cancer (2017) 0.75
Loss of caveolin-1 alters extracellular matrix protein expression and ductal architecture in murine mammary glands. PLoS One (2017) 0.75
Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs (2017) 0.75
Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther (2016) 0.75
Annexin A2 Coordinates STAT3 to Regulate the Invasion and Migration of Colorectal Cancer Cells In Vitro. Gastroenterol Res Pract (2016) 0.75
Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype. Sci Rep (2016) 0.75
Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. Oncol Lett (2017) 0.75
ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer. Sci Rep (2017) 0.75
FGFR4 Arg388 is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition. Cancer Res Treat (2016) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56
Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2006) 6.64
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol (2003) 3.26
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J (2010) 3.05
Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75
Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc Natl Acad Sci U S A (1977) 2.65
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res (2008) 2.63
MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol (1996) 2.62
Signal co-operation between integrins and other receptor systems. Biochem J (2009) 2.59
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol (2006) 2.25
Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol (2006) 2.21
Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem (2006) 2.15
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 2.13
Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene (2010) 1.80
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer (2002) 1.68
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol (2011) 1.52
Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans (2004) 1.49
TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene (2012) 1.43
The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol (2002) 1.40
Role of transforming growth factor-beta in cancer progression. Future Oncol (2006) 1.34
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. EMBO J (1999) 1.23
A new small-molecule Stat3 inhibitor. Chem Biol (2006) 1.20
Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res (2009) 1.19
Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer (2012) 1.18
A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes. J Biol Chem (1999) 1.15
Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer (2011) 1.12
Targeting EGFR in Triple Negative Breast Cancer. J Cancer (2011) 1.09
Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.04
EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun (1995) 1.04
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. J Oncol (2009) 1.02
Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol Cell Biol (1987) 1.01
EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J Cell Physiol (2000) 0.96
E3-13.7 integral membrane proteins encoded by human adenoviruses alter epidermal growth factor receptor trafficking by interacting directly with receptors in early endosomes. Mol Biol Cell (2000) 0.92
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for stat-mediated transcription. J Biol Chem (1998) 0.88
Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. PLoS One (2013) 0.87
Gab1 signaling is regulated by EGF receptor sorting in early endosomes. Oncogene (2006) 0.82
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res (2011) 0.81
EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes. Biochem Biophys Res Commun (1999) 0.81
Expression and prognostic value of EGFR in invasive breast cancer. Oncol Rep (2005) 0.77
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem (2006) 2.47
TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest (2012) 2.44
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. Genome Res (2009) 2.31
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res (2007) 2.28
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A (2010) 2.06
DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal (2010) 2.04
Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat Methods (2008) 2.02
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A (2002) 1.94
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res (2006) 1.69
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell (2003) 1.63
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem (2002) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis (2008) 1.45
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem (2009) 1.37
Role of transforming growth factor-beta in cancer progression. Future Oncol (2006) 1.34
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30
Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell (2004) 1.29
Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.28
Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol (2008) 1.26
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 1.26
CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity. Am J Physiol Gastrointest Liver Physiol (2004) 1.21
Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol (2004) 1.20
Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20
Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res (2004) 1.19
Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia. Lab Invest (2007) 1.18
A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor. J Biol Chem (2005) 1.18
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res (2010) 1.16
Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis (2007) 1.15
CHD7 functions in the nucleolus as a positive regulator of ribosomal RNA biogenesis. Hum Mol Genet (2010) 1.13
Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol (2010) 1.13
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion. Mol Cancer Res (2008) 1.11
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia (2011) 1.09
NetSlim: high-confidence curated signaling maps. Database (Oxford) (2011) 1.09
Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res (2008) 1.08
Fibulin-5 function during tumorigenesis. Future Oncol (2005) 1.05
Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β. Mol Biol Cell (2013) 1.02
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
Global mutational profiling of formalin-fixed human colon cancers from a pathology archive. Mod Pathol (2012) 1.01
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01
CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through Bim-mediated intrinsic apoptosis. PLoS One (2010) 1.00
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem (2009) 0.98
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle (2009) 0.98
Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther (2007) 0.98
Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res (2011) 0.98
Coupling cellular localization and function of checkpoint kinase 1 (Chk1) in checkpoints and cell viability. J Biol Chem (2012) 0.97
Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr (2011) 0.97
In vivo dual substrate bioluminescent imaging. J Vis Exp (2011) 0.97
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res (2013) 0.96
Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering. J Invest Dermatol (2004) 0.96
How do alignment programs perform on sequencing data with varying qualities and from repetitive regions? BioData Min (2012) 0.96
Decreased amiloride-sensitive Na+ absorption in collecting duct principal cells isolated from BPK ARPKD mice. Am J Physiol Renal Physiol (2003) 0.95
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol (2013) 0.95
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res (2014) 0.94
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells. Cells Tissues Organs (2010) 0.94
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Res Treat (2013) 0.93
Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations. J Biol Chem (2009) 0.93
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
From spindle checkpoint to cancer. Nat Genet (2004) 0.90
Autosomal recessive polycystic kidney disease epithelial cell model reveals multiple basolateral epidermal growth factor receptor sorting pathways. Mol Biol Cell (2010) 0.89
Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor. Biochemistry (2008) 0.88
Host cell autophagy modulates early stages of adenovirus infections in airway epithelial cells. J Virol (2012) 0.87
Differential binding modes of the bromodomains of CREB-binding protein (CBP) and p300 with acetylated MyoD. Biochem Biophys Res Commun (2008) 0.87
Fibulin-5 promotes wound healing in vivo. J Am Coll Surg (2004) 0.86
Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. Future Oncol (2009) 0.86
Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation. Cell Commun Adhes (2009) 0.86
Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor beta signaling. BMC Cell Biol (2004) 0.85
Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci Rep (2011) 0.85